135 completed, 49 recruiting, 42 terminated, 33 active not recruiting. 101 Phase 2, 85 Not applicable, 63 Phase 1, 31 Early Phase 1, 19 Phase 3.
Follow Fluorodeoxyglucose F18: new trials by email Literature Review of Fluorodeoxyglucose F18 trials Research Report on Fluorodeoxyglucose F18
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 164 | 2026-10-14 | 2026-10-19 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| Multi-organ Imaging of Microvascular and Metabolic Function 18F-FDG, Positron Emission Tomography (PET) - Healthy Subjects (HS), Cardiovascular Diseases (CVD) | Early Phase 1 | Not yet recruiting | Massachusetts General Hospital | 60 | 2026-07-01 | 2026-05-22 |
| Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution 18F-FDG, Breast-dedicated PET camera - Breast Cancer | Early Phase 1 | Withdrawn | Stanford University | 2026-06-01 | 2026-05-29 | |
| 5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors 18F-FDG, 68Ga-MY - Lung Cancer, Breast Cancer | Not applicable | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2026-06-01 | 2026-05-15 |
| Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET 18F-FAPI-74, 18F-FDG, PET/CT - Breast Cancer, Metastatic Invasive Lobular Breast Cancer | Phase 2 | Not yet recruiting | Randy Yeh | 15 | 2026-06-01 | 2026-05-01 |
| Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma 18F-FDG - Urothelial Carcinoma | Not applicable | Recruiting | Peking University Cancer Hospital & Institute | 20 | 2026-05-31 | 2026-03-04 |
| Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging [18F]-FDG - HER2-positive Breast Cancer | Phase 1 / Phase 2 | Withdrawn | University of Alabama at Birmingham | 2026-03-01 | 2026-07-01 | |
| [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer Best Practice, Biopsy of Breast, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Washington | 22 | 2026-02-26 | 2026-05-19 |
| Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes 18F-FDG, [18F]F-PDL1-3 - Lung Cancer (NSCLC), Cervical Squamous Cell Cancer | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 50 | 2026-02-01 | 2026-09-29 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [18F]FAPI-74, [18F]FDG - Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-09-09 | 2026-05-19 |
Showing 20 of 322. Sign in to see all of them.
Breast Neoplasms (40) · Lung Neoplasms (30) · Carcinoma, Non-Small-Cell Lung (29) · Neoplasms (17) · Uterine Cervical Neoplasms (13) · Squamous Cell Carcinoma of Head and Neck (11) · Carcinoma, Hepatocellular (10) · Esophageal Neoplasms (10) · Alzheimer Disease (9) · Carcinoma, Renal Cell (9) · Glioblastoma (9) · Melanoma (9) · Rectal Neoplasms (9) · Sarcoma (9) · Brain Neoplasms (8)
National Cancer Institute (NCI) (37) · University of Washington (13) · Jonsson Comprehensive Cancer Center (12) · M.D. Anderson Cancer Center (11) · Peking University Cancer Hospital & Institute (11) · Stanford University (10) · Memorial Sloan Kettering Cancer Center (9) · Peking Union Medical College Hospital (7) · University of Utah (7) · Washington University School of Medicine (7) · City of Hope Medical Center (6) · Alliance for Clinical Trials in Oncology (5) · Mayo Clinic (5) · Ohio State University Comprehensive Cancer Center (5) · Abramson Cancer Center at Penn Medicine (4)
United States (211) · China (41) · Canada (23) · France (14) · United Kingdom (8) · Denmark (5) · Spain (5) · Netherlands (4) · Puerto Rico (4) · Australia (3) · Italy (3) · Finland (2) · Germany (2) · Ireland (2) · South Korea (2)
Hua Zhu (5) · Hannah Linden (4) · John M Hoffman, MD (3) · Zhaohui Zhu, MD (3) · Albert Koong (2) · Andreas Kjaer, MD (2) · Andrei Iagaru (2) · Christina Poh (2) · Dawid Schellingerhout (2) · Donald Blaufox, MD (2) · Esther Mena Gonzalez, M.D. (2) · Guobao Wang, PhD (2) · Jason M Johnson (2) · Jeffrey Yap, PhD (2) · Jeremie Calais (2)
PMID 30573690, PMID 37505794, PMID 40135712, PMID 10813118, PMID 14688710, PMID 17634125, PMID 17634488, PMID 17882490, PMID 18355490, PMID 18640307, PMID 19487962, PMID 21617977, PMID 21896345, PMID 22105720, PMID 22326218, PMID 22819172, PMID 22989664, PMID 23187748, PMID 23344409, PMID 23455520, PMID 23496877, PMID 23640206, PMID 24170452, PMID 24309981, PMID 24764034, PMID 25113840, PMID 25783515, PMID 25965900, PMID 26062933, PMID 26405167, PMID 26611425, PMID 26672686, PMID 26703796, PMID 26892585, PMID 26956325, PMID 26988861, PMID 27153497, PMID 27236466, PMID 27256597, PMID 27607176, PMID 27659017, PMID 27683031, PMID 27690345, PMID 27710970, PMID 27729297, PMID 28178885, PMID 28360208, PMID 28911922, PMID 28978463, PMID 29650773
P30CA008748 (6), U10CA180820 (6), P30CA015704 (4), P30CA033572 (4), P30CA043703 (4), U10CA180821 (4), U10CA180868 (4), U10CA180886 (4), P30CA016672 (3), U01CA079778 (3), U01CA080098 (3), N01CM62206 (2), N01CM62207 (2), P30CA006973 (2), P30CA015083 (2)